← back to search

Federico Pérez

Case Western Reserve University · US
Area of research
Molecular Medicine · Pharmacology
Research interest
Research focused on Pseudomonas aeruginosa and Ceftazidime, with related work in Ceftazidime/avibactam, Retrospective cohort study, Microbiology. Notable publications include 'Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae', 'Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective...', and 'Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?'.
h-index
citations
2,070
works
15
NIH funding
primary concept
email

Recent publications

A molecular analysis of meropenem–vaborbactam non-susceptible KPC-producing <i>Klebsiella pneumoniae</i>
Antimicrobial Agents and Chemotherapy 2024cited by 7position: middledoi
Characteristics of community-acquired carbapenem-resistant Enterobacterales
Journal of Antimicrobial Chemotherapy 2022cited by 29position: middledoi
Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing
PLoS ONE 2022cited by 22position: middledoi
Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration
JAMA Network Open 2019cited by 36position: middledoi
Higher MICs (&amp;gt;2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam
Open Forum Infectious Diseases 2019cited by 33position: middledoi
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
Clinical Infectious Diseases 2017cited by 641position: middledoi
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
The Lancet Infectious Diseases 2017cited by 518position: middledoi
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Antimicrobial Agents and Chemotherapy 2017cited by 286position: middledoi
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa
Clinical Infectious Diseases 2017cited by 141position: middledoi
Application of “Precision Medicine” Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient
Clinical Infectious Diseases 2017cited by 17position: middledoi
“Double carbapenem” and oral fosfomycin for the treatment of complicated urinary tract infections caused by <i>bla</i><sub>NDM</sub>‐harboring Enterobacteriaceae in kidney transplantation
Transplant Infectious Disease 2017cited by 16position: middledoi
A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Antimicrobial Agents and Chemotherapy 2016cited by 151position: middledoi
Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II
Clinical Infectious Diseases 2015cited by 61position: middledoi
Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Containing <i>bla</i> <sub>VIM-2</sub> and Elements of Salmonella Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio
Antimicrobial Agents and Chemotherapy 2014cited by 43position: firstdoi
OqxAB, a Quinolone and Olaquindox Efflux Pump, Is Widely Distributed among Multidrug-Resistant Klebsiella pneumoniae Isolates of Human Origin
Antimicrobial Agents and Chemotherapy 2013cited by 69position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Robert A. Bonomo · Louis Stokes Cleveland VA Medical Center11 papers (2013–2024)Andrea M. Hujer · Louis Stokes Cleveland VA Medical Center7 papers (2013–2024)Barry N. Kreiswirth · Center for Discovery5 papers (2013–2024)Michael R. Jacobs · Case Western Reserve University5 papers (2014–2024)Lilian M. Abbo · University of Miami5 papers (2017–2022)Laura J. Rojas · Case Western Reserve University5 papers (2017–2024)Susan D. Rudin · Louis Stokes Cleveland VA Medical Center4 papers (2013–2017)Vance G. Fowler · Duke University4 papers (2015–2024)Steven H. Marshall · Louis Stokes Cleveland VA Medical Center4 papers (2013–2024)David van Duin · University of North Carolina at Chapel Hill4 papers (2013–2024)Liang Chen · South China Agricultural University4 papers (2013–2024)David L. Paterson · Department of Public Health3 papers (2013–2017)Kristine M. Hujer · Case Western Reserve University3 papers (2015–2024)Octavio Martínez · University of Miami3 papers (2017–2022)Henry F. Chambers · CNR de la Résistance aux Antibiotiques3 papers (2015–2024)Alejandro J. Vila · University of Houston3 papers (2014–2022)Armando Pérez-Cardona · Jackson Memorial Hospital3 papers (2017–2022)Rossana Rosa · Horizon Health Network3 papers (2017–2017)Kalyan D. Chavda · Nanostring Technologies (United States)2 papers (2014–2015)Philip N. Rather · Emory University2 papers (2013–2014)